Skip to main content
Clinical Trials/DRKS00029910
DRKS00029910
Recruiting
未知

Effects of robot-assisted and conventional gait training on walking ability, basic activities of daily living, walking, functional mobility, falls related self-efficacy and quality of life in patients after stroke: a randomised controlled trial - RAGT-Neur-2

Tyromotion GmbH0 sites100 target enrollmentOctober 17, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
I60
Sponsor
Tyromotion GmbH
Enrollment
100
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 17, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Potential study participants must meet all listed inclusion criteria to be eligible for participating in this clinical investigation. Patients will be recruited into this clinical investigation if they have been diagnosed with a first\-ever ischemic or haemorrhagic stroke in the (early and late) subacute phase (\<6 months post stroke) or in the chronic phase (\=6 months post stroke) (Bernhardt et al., 2017\), have an impairment in walking according to the neurological exam assessed by a neurologist and a Functional Ambulation Categories (FAC) score of 0\-4/5 (Wade, 1992\). Patients with subacute, severe stroke who are non\-ambulatory are eligible if they are able to sit unsupported (i.e., without holding onto supports such as the edge of the bed), with feet supported and can be verticalised for at least 1 hour twice a day. Stroke is diagnosed based on current criteria according to the S1 Guideline (2017\) (Hennerici \& Kern, 2017\) or the S2e Guideline of the German Society of Neurology (2021\) (Ringleb et al., 2021\).
  • Adult patients aged between 18 and 99 of female, male and diverse genders, of any ethnicity and German speaking verbally and written language will be included.
  • Patients should be able to understand the patient information and study procedure and follow instructions (\=21/30 points on the Mini Mental State Examination (MMSE)) (Folstein et al., 1975\). Patients will only be included if they appear able to participate in this clinical investigation over its complete duration, which will be evaluated by the study PI.

Exclusion Criteria

  • Patients will be excluded from this clinical investigation if they meet any of the criteria listed as follows.
  • \- Concomitant disease (such as malignant disease, other severe neurological, orthopaedic or psychiatric diseases, cardiac contraindications)
  • \- Acute, pronounced pain symptoms despite conventional pain therapy
  • \- Joint contractures, joint arthrodesis or severe spasticity (stiff/immobile joint) in the area of the lower extremity, extremely disproportionate growth of the legs and/or spinal column
  • \- Body weight of less than 15 kg or more than 180 kg
  • \- Body height of less than 100 cm or more than 200 cm
  • \- Psychiatric diseases impairing patients’ compliance ability
  • \- Significant reduction in bone density (osteopenia or osteoporosis), increased risk of bone fracture
  • \- Osseous or joint instability (non\-consolidated fractures, osteogenesis imperfecta, unstable spinal column, pseudoarthrosis, hip, knee or ankle joint instability)
  • \- Cardiac contraindications

Outcomes

Primary Outcomes

Not specified

Similar Trials